Vaccine makers Pfizer PFE.N and BioNTech 22UAy.DE halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to ...

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment ...

Vaccine maker's critics hope for new attorney general to reverse Pam Bondi's hostility to clinical trial whistleblower's ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

Pfizer and BioNTech have halted a U.S. study of their updated COVID-19 vaccine in adults ages 50-64 due to slow enrollment, a Pfizer spokesperson confirmed to Becker’s. “We can confirm our ...

BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at straitstimes.com. Read more at straitstimes.com.

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. (Jeenah Moon via Getty Images) This story was originally published ...